ARTICLE | Emerging Company Profile

Terremoto carves out new chemical space with lysine-based covalency platform

Backed by Third Rock and OrbiMed, start-up aims to balance portfolio with best-in-class treatments and therapies against previously undruggable targets

May 25, 2022 2:20 PM UTC

Terremoto is emerging from stealth with $75 million to expand the small molecule space through the use of covalent chemistry to target the amino acid lysine.

On Wednesday, South San Francisco-based Terremoto Biosciences Inc. said OrbiMed Advisors and Third Rock Ventures led its $75 million series A round...